Bone resorption

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Bone resorption
Light micrograph of an osteoclast displaying typical distinguishing characteristics: a large cell with multiple nuclei and a "foamy" cytosol.
Classification and external resources
Specialty rheumatology
ICD-10 M80
ICD-9-CM 733.99
eMedicine ent/646
MeSH D001862

Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the tissue in bones[1] and release the minerals, resulting in a transfer of calcium from bone tissue to the blood.[2]

The osteoclasts are multi-nucleated cells that contain numerous mitochondria and lysosomes. These are the cells responsible for the resorption of bone. Osteoclasts are generally present on the outer layer of bone, just beneath the periosteum. Attachment of the osteoclast to the osteon begins the process. The osteoclast then induces an infolding of its cell membrane and secretes collagenase and other enzymes important in the resorption process. High levels of calcium, magnesium, phosphate and products of collagen will be released into the extracellular fluid as the osteoclasts tunnel into the mineralized bone. Osteoclasts are also prominent in the tissue destruction commonly found in psoriatic arthritis and other rheumatology related disorders.[3]

The human body is in a constant state of bone remodeling.[4] Bone remodelling is a process which maintains bone strength and ion homeostatis by replacing discrete parts of old bone with newly synthesized packets of proteinaceous matrix.[5] Bone is resorbed by osteoclasts, and is deposited by osteoblasts in a process called ossification.[6] Osteocyte activity also plays a key role in this process. Conditions that result in a decrease in bone mass, can either be caused by an increase in resorption, or a decrease in ossification.

During childhood, bone formation exceeds resorption, but as the aging process occurs, resorption exceeds formation.[5]

Bone resorption rates are much higher in post-menopausal older women due to estrogen deficiency related with menopause.[7] Common treatments include drugs that increase bone mineral density. Bisphosphonates, RANKL inhibitors, SERMs—selective oestrogen receptor modulators, hormone replacement therapy and calcitonin are some of the common treatments.[8] Light weight bearing exercise also tends to eliminate the negative effects of bone resorption.[9]


Bone resorption is highly stimulated or inhibited by signals from other parts of the body, depending on the demand for calcium.

Calcium-sensing membrane receptors in the parathyroid gland monitor calcium levels in the extracellular fluid. Low levels of calcium stimulates the release of parathyroid hormone (PTH) from chief cells of the parathyroid gland.[4] In addition to its effects on kidney and intestine, PTH also increases the number and activity of osteoclasts. The increase in activity of already existing osteoclasts is the initial effect of PTH, and begins in minutes and increases over a few hours.[4] Continued elevation of PTH levels increases the abundance of osteoclasts. This leads to a greater resorption of calcium and phosphate ions.[4]

High levels of calcium in the blood, on the other hand, leads to decreased PTH release from the parathyroid gland, decreasing the number and activity of osteoclasts, resulting in less bone resorption. Vitamin D increases absorption of calcium and phosphate in the intestinal tract, leading to elevated levels of plasma calcium,[4] and thus lower bone resorption.

Calcitriol (1,25-dihydroxycholecalciferol) is the active form of vitamin D3.[10] It has numerous functions involved in blood calcium levels. Recent research indicates that calcitriol leads to a reduction in osteoclast formation, and bone resorption.[11][12] Although it follows that an increase in vitamin D3 intake should lead to a decrease in bone resorption, it has been shown that oral administration of vitamin D does not linearly correlate to increased serum levels of calcifediol,[13] the precursor to calcitriol.

Calcitonin is a hormone secreted by the thyroid in humans. Calcitonin decreases osteoclast activity, and decreases the formation of new osteoclasts, resulting in decreased resorption.[4] Calcitonin has a greater effect in young children than in adults, and plays a smaller role in bone remodeling than PTH.[4]

In some cases where bone resorption outpaces ossification, the bone is broken down much faster than it can be renewed. The bone becomes more porous and fragile, exposing people to the risk of fractures. Depending on where in the body bone resorption occurs, additional problems like tooth loss can also arise. This can be caused by conditions such as hypoparathyroidism and hypovitaminosis D or even decreased hormonal production in the elderly. Some diseases with symptoms of decreased bone density are osteoporosis, and rickets.

Some people who experience increased bone resorption and decreased bone formation are astronauts. Due to the condition of being in a zero-gravity environment, astronauts do not need to work their musculoskeletal system as hard as when on earth. Ossification decreases due to a lack of stress, while resorption increases, leading to a net decrease in bone density.[14]

Chronic Alcoholism and Bone resorption[edit]

The effects of alcohol on bone mineral density (BMD) are well-known and well-studied in animal and human populations. Through direct and indirect pathways, prolonged ethanol exposure increases fracture risk by decreasing bone mineral density and promoting osteoporosis. Indirect effects of alcohol abuse occur via growth hormone, sex steroids, and oxidative stress. Growth hormone is an important regulator of bone growth and remodeling in adults, and it acts via insulin like growth factor I (IGF1) to stimulate osteoblastic differentiation.[15] Chronic alcoholism decreases the levels of IGF1, which suppresses the ability of GH to increase bone mineral density.[15] Increasing alcohol consumption is also linked with decreasing testosterone and serum estradiol levels, which in turn lead to the activation of RANK (a TNF receptor) protein that promote osteoclast formation.[16] Oxidative stress results when ethanol induces NOX expression, resulting in ROS production in osteoblasts which can untimately result in cell senescence.[17] Direct effects of chronic alcoholism are apparent in osteoblasts, osteoclasts and osteocytes. Ethanol suppresses the activity and differentiation of osteoblasts, but at the same time, it has a direct effect on osteoclast activity. This results in an increased bone resorption rate and a decreased bone mineral density due to increased pit numbers and pit areas in the bone.[18][19] Research has shown that viable osteocytes (another type of bone cell) may prevent osteoclastogenesis, whereas apoptotic osteocytes tend to induce osteoclast stimulation. Stimulation of osteocyte apoptosis by alcohol exposure may explain decreased bone mineral density in chronic drinkers.[19]

See also[edit]


  1. ^ Bone Resorption at the US National Library of Medicine Medical Subject Headings (MeSH)
  2. ^ Teitelbaum SL. (2000). "Bone resorption by osteoclasts.". Science. 289 (5484): 1504–8. doi:10.1126/science.289.5484.1504. PMID 10968780. 
  3. ^ Mensah, Kofi A.; Schwarz, Edward M.; Ritchlin, Christopher T. (2008-08-01). "Altered Bone Remodeling in Psoriatic Arthritis". Current Rheumatology Reports. 10 (4): 311–317. doi:10.1007/s11926-008-0050-5. ISSN 1523-3774. PMC 2656567free to read. PMID 18662512. 
  4. ^ a b c d e f g Guyton and Hall Textbook of Medical Physiology, 12th Edition. ISBN 1416045740
  5. ^ a b Clarke, Bart (2008-11-01). "Normal Bone Anatomy and Physiology". Clinical Journal of the American Society of Nephrology. 3 (Suppl 3): S131–S139. doi:10.2215/CJN.04151206. ISSN 1555-9041. PMC 3152283free to read. PMID 18988698. 
  6. ^ Maurel, D. B.; Jaffre, C.; Rochefort, G. Y.; Aveline, P. C.; Boisseau, N.; Uzbekov, R.; Gosset, D.; Pichon, C.; Fazzalari, N. L. (2011-09-01). "Low bone accrual is associated with osteocyte apoptosis in alcohol-induced osteopenia". Bone. 49 (3): 543–552. doi:10.1016/j.bone.2011.06.001. ISSN 1873-2763. PMID 21689804. 
  7. ^ Feng, Xu; McDonald, Jay M. (2011-01-01). "Disorders of Bone Remodeling". Annual Review of Pathology. 6: 121–145. doi:10.1146/annurev-pathol-011110-130203. ISSN 1553-4006. PMC 3571087free to read. PMID 20936937. 
  8. ^ Russell, G.; Mueller, G.; Shipman, C.; Croucher, P. (2001-01-01). "Clinical disorders of bone resorption". Novartis Foundation Symposium. 232: 251–267; discussion 267–271. ISSN 1528-2511. PMID 11277085. 
  9. ^ Shanb, Alsayed A.; Youssef, Enas F. (2014-01-01). "The impact of adding weight-bearing exercise versus nonweight bearing programs to the medical treatment of elderly patients with osteoporosis". Journal of Family & Community Medicine. 21 (3): 176–181. doi:10.4103/2230-8229.142972. ISSN 1319-1683. PMC 4214007free to read. PMID 25374469. 
  10. ^ Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al., editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. 3, Overview of Vitamin D. Available from:
  11. ^ Kikuta J, Kawamura S, Okiji F, Shirazaki M, Sakai S, Saito H, Ishii M (Apr 2013). "Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D.". Proc Natl Acad Sci U S A. 110 (17): 7009–13. doi:10.1073/pnas.1218799110. PMID 23569273. 
  12. ^ Yamamoto Y, Yoshizawa T, Fukuda T, Shirode-Fukuda Y, Yu T, Sekine K, Sato T, Kawano H, Aihara K, Nakamichi Y, Watanabe T, Shindo M, Inoue K, Inoue E, Tsuji N, Hoshino M, Karsenty G, Metzger D, Chambon P, Kato S, Imai Y (Mar 2013). "Vitamin D receptor in osteoblasts is a negative regulator of bone mass control". Endocrinology. 154 (3): 1008–20. doi:10.1210/en.2012-1542. PMID 23389957. 
  13. ^ Stamp TC, Haddad JG, Twigg CA (Jun 1977). "Comparison of oral 25-hydroxycholecalciferol, vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin D.". Lancet. 1 (8026): 1341–3. doi:10.1016/s0140-6736(77)92553-3. PMID 69059. 
  14. ^ Iwamoto J, Takeda T, Sato Y (Jun 2005). "Interventions to prevent bone loss in astronauts during space flight". Keio J Med. 54 (2): 55–9. doi:10.2302/kjm.54.55. PMID 16077253. 
  15. ^ a b Maddalozzo, G. F.; Turner, R. T.; Edwards, C. H. T.; Howe, K. S.; Widrick, J. J.; Rosen, C. J.; Iwaniec, U. T. (2009-09-01). "Alcohol alters whole body composition, inhibits bone formation, and increases bone marrow adiposity in rats". Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 20 (9): 1529–1538. doi:10.1007/s00198-009-0836-y. ISSN 1433-2965. PMID 19238309. 
  16. ^ Ronis, Martin J. J.; Wands, Jack R.; Badger, Thomas M.; de la Monte, Suzanne M.; Lang, Charles H.; Calissendorff, Jan (2007-08-01). "Alcohol-induced disruption of endocrine signaling". Alcoholism, Clinical and Experimental Research. 31 (8): 1269–1285. doi:10.1111/j.1530-0277.2007.00436.x. ISSN 0145-6008. PMID 17559547. 
  17. ^ Chen, Jin-Ran; Shankar, Kartik; Nagarajan, Shanmugam; Badger, Thomas M.; Ronis, Martin J. J. (2008-01-01). "Protective effects of estradiol on ethanol-induced bone loss involve inhibition of reactive oxygen species generation in osteoblasts and downstream activation of the extracellular signal-regulated kinase/signal transducer and activator of transcription 3/receptor activator of nuclear factor-kappaB ligand signaling cascade". The Journal of Pharmacology and Experimental Therapeutics. 324 (1): 50–59. doi:10.1124/jpet.107.130351. ISSN 1521-0103. PMID 17916759. 
  18. ^ Bonewald, Lynda F. (2011-02-01). "The amazing osteocyte". Journal of Bone and Mineral Research. 26 (2): 229–238. doi:10.1002/jbmr.320. ISSN 1523-4681. PMC 3179345free to read. PMID 21254230. 
  19. ^ a b Verborgt, Olivier; Tatton, Nadine A.; Majeska, Robert J.; Schaffler, Mitchell B. (2002-05-01). "Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation?". Journal of Bone and Mineral Research. 17 (5): 907–914. doi:10.1359/jbmr.2002.17.5.907. ISSN 0884-0431. PMID 12009022.